# A Study of CLSP 5282 in HLA-A*03:01 Positive Adult Patients With Solid Tumors (SENTINEL-101)

> **NCT07650357** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Clasp Therapeutics, Inc.** · enrollment: 140 (estimated)

## Conditions studied

- Advanced Solid Tumor
- Non Small Cell Lung Cancer
- Pancreatic Carcinoma
- Colorectal Cancer

## Interventions

- **DRUG:** CLSP-5282

## Key facts

- **NCT ID:** NCT07650357
- **Lead sponsor:** Clasp Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-07
- **Primary completion:** 2029-05
- **Final completion:** 2029-07
- **Target enrollment:** 140 (ESTIMATED)
- **Last updated:** 2026-06-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07650357

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07650357, "A Study of CLSP 5282 in HLA-A*03:01 Positive Adult Patients With Solid Tumors (SENTINEL-101)". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07650357. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*